Market Launch Research Articles

Analysis of Editorial Planning and Insights from International Bestsellers in the Age of Intelligence

In the era of intelligence, the book publishing industry is experiencing new vitality but is also facing challenges such as severe homogenization and increasing competition. Taking the British bestseller The Thursday Murder Club as a case study, this paper conducts an in-depth analysis of the book series' publishing timing, editorial planning, and marketing strategies. Through this case study, the paper summarizes successful experiences and insights into creating professional bestsellers, offering references and suggestions for the publishing industry to address market challenges and launch bestsellers. The study points out that the publishing industry should pay attention to trends and changes, accurately grasp market demand, adjust marketing strategies promptly, and emphasize collaboration and joint promotion.

Remimazolam-Update on basic pharmacologic principles and clinical potential

In recent years the still relatively new short-acting benzodiazepine remimazolam has been approved and clinically implemented in several countries and regions. Remimazolam is also now approved in the EU and the market launch in Germany is expected in the not too distant future. This is therefore a good point in time to summarize the current evidence for various areas of application, including general anesthesia, sedation and intensive care medicine as well as different dosing schemes.

A capability to promote the utilization of human samples for improving the ‍clinical response predictability in the pharmaceutical company

An issue in drug discovery research at pharmaceutical companies is the decline in the probability of market launch, and there is a need to improve the proof-of-concept (POC) acquisition rate by further improving clinical predictability. For this purpose, we need to deepen our understanding of human pathophysiology, and to make efficient of drug discovery research by utilizing human samples and data due to the change in mindset from "animals" to "humans" at the drug discovery research stage. In particular, with the aim of improving the efficiency of drug discovery research by utilizing human samples/data, we have established a human sample utilization support capability, then we are supporting the acquisition of appropriate human samples/data to meet each drug research need with collecting information on organizations that can provide various human samples and accumulating know-how on obtaining human samples/data. In addition, we have built a one-stop support system for surveying human samples/data, negotiating, and contracting with the organizations, obtaining ethical committee approvals, importing samples, and dealing with customs clearance. As results, our researchers can obtain high-quality human samples/data to meet their research needs rapidly/easily. By establishing this capability, the number of the research projects that implement target validation, pharmacological evaluation, BM identification, and patient stratification, etc. using human samples/data from the early stage of drug discovery, has increased, and then, the evidence obtained by using human samples/data contribute to create drug candidates with high probability of clinical effect. We will introduce our activities while showing the support flow that was actually constructed.

Distributed polymer optical fiber sensors using digital I-OFDR for geotechnical infrastructure health monitoring

We present a distributed polymer optical fiber sensor system for deformation monitoring of geotechnical infrastructure. The sensor system is based on the digital incoherent optical frequency domain reflectometry (I-OFDR) for the detection of local strain events along a perfluorinated polymer optical fiber (PF-POF) used as a sensing fiber. For the best possible load transfer, the PF-POFs were integrated onto geotextiles which pose a sensor carrier for the sensing fiber. By using elastic PF-POF instead of a standard glass fiber as a sensing fiber the strain range of geotextile-integrated fiber optic sensors could be extended up to 10 % in accordance with the end-user requirements. In order to reduce overall costs of the sensor system and achieve its robustness required for use on site, the standard vector network analyzer used by default was replaced by an integrated digital board for optical frequency domain analysis. This implementation showed a significant improvement in the dynamic range and sensitivity compared to the previous measurement system based on the conventional network analyzer. The functionality of the entire sensor system was proven in the field test during the installation of two geomats with integrated PF-POFs embedded into a road embankment in a section of the B 91 federal road near Werschen in the greater Leipzig area. To monitor the installation-related changes in the condition of both sensor-based geomats several control measurements on the embedded PF-POFs and co-integrated reference glass fibers were carried as the construction works progressed. The measurements recorded in the field confirm the great potential of the selected PF-POF used as the distributed fiber optic strain sensor. The future management of the remaining challenges of industrial strain-coupled sensor integration can result in a successful market launch of the PF-POF-sensor integrated into geosynthetics. The sensor system is ready to be used for practical application.

"Keep it a secret": leaked documents suggest Philip Morris International, and its Japanese affiliate, continue to exploit science for profit.

The tobacco industry has a long history of manipulating science to conceal the harms of its products. As part of its proclaimed transformation, the world's largest tobacco company, Philip Morris International (PMI), states it conducts "transparent science". This paper uses recently leaked documents from PMI and its Japanese affiliate, Philip Morris Japan (PMJ), to examine its contemporary scientific practices. 23 documents dating 2012 through 2020 available from Truth Tobacco Industry Documents Library were examined using Forster's hermeneutic approach to analysing corporate documentation. Thematic analysis using the Science for Profit Model was conducted to assess whether PMI/PMJ employed known corporate strategies to influence science in their interests. PMJ contracted a third-party external research organisation, CMIC, to covertly fund a study on smoking cessation conducted by Kyoto University academics. No public record of PMJ's funding or involvement in this study was found. PMJ paid life sciences consultancy, FTI-Innovations, ¥3,000,000 (approx. £20,000) a month between 2014 and 2019 to undertake extensive science-adjacent work, including building relationships with key scientific opinion leaders and using academic events to promote PMI's science, products and messaging. FTI-Innovation's work was hidden internally and externally. These activities resemble known strategies to influence the conduct, publication and reach of science, and conceal scientific activities. The documents reveal PMI/PMJ's recent activities mirror past practices to manipulate science, undermining PMI's proclaimed transformation. Tobacco industry scientific practices remain a threat to public health, highlighting the urgent need for reform to protect science from the tobacco industry's vested interests.Implications: Japan is a key market for PMI, being a launch market for IQOS and having the highest heated tobacco product use globally. Our findings, in conjunction with other recent evidence, challenge PMI's assertion that it is a source of credible science and cast doubt on the quality and ethical defensibility of its research, especially its studies conducted in Japan. This, in turn, brings into question the true public health impacts of its products. There is urgent need to reform the way tobacco-related science is funded and conducted. Implementation of models through which research can be funded using the industry's profits while minimising its influence should be explored.

Fostering well-being: Exploring the influence of user-AI assistant relationship types on subjective well-being

As one of the essential components of daily life, artificial intelligence (AI) assistants gradually form a relationship with users as either servant or partner. This study employed a mixed-methods approach integrating both quantitative and qualitative methodologies to examine the influence of various user-AI assistant relationship types on subjective well-being. The results indicate that partnerships are more conducive to fostering subjective well-being in users than master-servant relationships. This influence is mediated through social support, which encompasses both informational support and emotional support, and is moderated by the presence of feelings of social loneliness. These findings contribute to the available literature on user-AI relationships and subjective well-being and can inform the market launch of AI assistants.

Direct and indirect effects of degree of interdisciplinarity on firms' innovation performance: The moderating role of firms' capabilities

AbstractCombinations of heterogeneous knowledge from different scientific domains may drive highly innovative outcomes. Our study investigates whether firms can benefit from interdisciplinary research and development (R&D) activities by also reflecting on the potential negative consequences of increasing complexity of outcome validation activities at later stages of innovation processes. We explore which resources and organizational capabilities may influence the efficacy of interdisciplinary R&D activities. We examine whether the available financial slack, collaborations with universities, and a high betweenness centrality in scientific networks may promote the flexibility, scope, and efficiency of knowledge integration, and thus moderate the direct and mediated relationships between the degree of interdisciplinarity (DoI) of a firm's R&D activities and innovation performance. To test our hypotheses, we performed an analysis of medical technology firms that are highly dependent on interdisciplinary R&D. We collected a panel dataset of R&D activities and successful market launches of new products from 79 large medical technology firms between 1997 and 2021. The measurement of a firm's DoI is based on a novel approach involving neural networks in a bibliographic data graph. Our results suggest that firms can improve their innovation performance if they conduct interdisciplinary R&D activities. However, higher levels of DoI also increase the complexity of the required outcome validation, which reduces a firm's innovation performance. We also found that high levels of financial slack help to overcome barriers of implementing interdisciplinary R&D activities. Collaborations with universities, and good access to knowledge in scientific networks, further foster interdisciplinary knowledge application in new product development.

Inventions, public subsidies and market launch: opportunities and limits of patenting support in Argentina

Inventions, public subsidies and market launch: opportunities and limits of patenting support in Argentina

Overview on Pharmacovigilance: Ensuring Medication Safety

Pharmacovigilance plays a pivotal role in ensuring drug safety by monitoring and evaluating the effects of medications before and after their market launch. In India, a rapidly expanding pharmaceutical industry coupled with a diverse patient population and growing drug consumption necessitates robust pharmacovigilance measures. This abstract highlights the need for pharmacovigilance in India, emphasizing factors such as the expansion of the pharmaceutical sector, diverse patient demographics, increased drug consumption, limited awareness and reporting, regulatory compliance, globalization of clinical trials, and emerging safety concerns. The Pharmacovigilance Programme of India (PvPI) serves as a cornerstone for patient safety, focusing on data collection, signal detection, capacity building, and regulatory collaboration. Reporting adverse drug reactions (ADRs) to PvPI is crucial, and various reporting methods, including online reporting, Vigiflow software, ADR reporting forms, direct communication, telephone reporting, and email, are discussed. Additionally, advice on what to report, who can report, where to report, and the handling of submitted information is provided to encourage effective ADR reporting. Overall, pharmacovigilance in India is essential for ensuring the safe and effective use of pharmaceutical products, protecting public health, and minimizing risks associated with medications.

An Empirical Analysis of New Product Development Success Among Automotive Industry Vendors in Malaysia

New product development in the automotive industry necessitates significant upfront investment, given the uncertainty of a product's competitiveness upon market launch. Hence, industries strive to comprehend and evaluate crucial success factors during implementation phases. This paper delves into the findings of an empirical qualitative analysis study on the success of New Product Development (NPD) in order to provide deeper insights into these success factors. The study delineates three primary dimensions: IT capability, new product development process, and new product development strategy. Conducted within the Malaysian automotive industry, the empirical results affirm the criticality of these factors to success.

Drug development advances in human genetics-based targets.

Drug development is a long and costly process, with a high degree of uncertainty from the identification of a drug target to its market launch. Targeted drugs supported by human genetic evidence are expected to enter phase II/III clinical trials or be approved for marketing more quickly, speeding up the drug development process. Currently, genetic data and technologies such as genome-wide association studies (GWAS), whole-exome sequencing (WES), and whole-genome sequencing (WGS) have identified and validated many potential molecular targets associated with diseases. This review describes the structure, molecular biology, and drug development of human genetics-based validated beneficial loss-of-function (LOF) mutation targets (target mutations that reduce disease incidence) over the past decade. The feasibility of eight beneficial LOF mutation targets (PCSK9, ANGPTL3, ASGR1, HSD17B13, KHK, CIDEB, GPR75, and INHBE) as targets for drug discovery is mainly emphasized, and their research prospects and challenges are discussed. In conclusion, we expect that this review will inspire more researchers to use human genetics and genomics to support the discovery of novel therapeutic drugs and the direction of clinical development, which will contribute to the development of new drug discovery and drug repurposing.

Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study.

Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. The literature has focused on their assessment, appraisal and market access solutions. No evidence on the costs sustained to implement CAR-T is available and a few studies reported the cost of the CAR-T clinical pathway, including the activities that are remunerated through inpatient or outpatient fee-for-service/episode. This paper aims at filling the information gap, assessing the cost of implementing CAR-T activity and the full cost of managing the CAR-T clinical pathway. Cost analysis relied on the Activity Based Costing approach, which was applied to two Italian healthcare organisations, both CAR-T Centres authorized by the regional governments with a minimum of 20 patients treated with the first two CAR-T therapies launched on the market. The cost of implementing CAR-T was estimated at €1.31million (calculated for one of the organizations with complete data). Most of these costs (77%) were generated by quality assurance activity. The mean cost per patient entering the CAR-T pathway (59 and 27) and surviving at follow-up (21 and 5) ranges from €48K to €57K and from €96K to €106K, respectively. Fees for hospitalization and infusion of gene therapy accounts for more than 70% of these costs. The actual hospitalisation cost varies greatly across patients and is in general lower than the fee-for-episode paid by the region to the hospital. Despite its limitations (exploratory nature; the time spent by staff on activities which are not remunerated through fees was estimated through interviews with the CAR-T coordinators; cost items are not fully comparable), this research highlighted the relevant organisational and economic impact of CAR-T and provided important insights for policy makers and healthcare managers: the necessity to invest resources in CAR-T implementation; the need for assessing activities which are not remunerated through fees for service / episode; the opportunity to shift from fee-for-episode/service to bundled payments for CAR-T clinical pathway.

Prediction of the Spatial and Temporal Adoption of an Energy Management System in Automated Dairy Cattle Barns in Bavaria—“CowEnergySystem”

In view of rising global demand, energy is becoming a significant cost factor in industry and society. In addition to the global players China, India, and the USA, Africa will also become a driver of the world’s primary energy demand in the future due to the rapidly growing developing countries. In addition to the armed conflicts in Ukraine and the Middle East, global energy markets are tense and volatile due to inflation and higher borrowing costs. Because of society’s desire to phase out the use of fossil fuels, the use of renewable energies is increasingly taking center stage worldwide and especially in Germany. Rural areas and agriculture, especially energy-intensive livestock farms, are particularly affected by this development and are therefore faced with additional economic challenges. Additional energy can be generated by using photovoltaic systems on the roofs of farm buildings or by utilizing the liquid manure from livestock farming in biogas plants. For these farms, such alternative sources of energy could open previously untapped potential and additional synergies for using their own inexpensive energy on the farm or supplying surplus electricity directly to the public grid as a market participant. Agriculture could thus serve as an actor in a decentralized energy supply and thus build up regional energy networks. However, intelligent electricity storage concepts and a corresponding energy management system (EMS) are essential to be able to utilize the potential for renewable energy generation at all, to coordinate both internal production processes and the varying energy demand and supply on the electricity grid. As agricultural production processes differ greatly from farm to farm and region to region, the introduction of an energy management system is strongly dependent on user acceptance. The purpose of this study is to use the web-based software tool ADOPT (CSIRO 2018) to predict the level of acceptance and the duration of the market launch of an EMS based on the region of Bavaria. Individual important influencing factors for the subsequent regional marketing concept are also identified.

SHELF FOR SERVING LINES DEVELOPMENT AND LAUNCHING TO THE MARKET

In today’s market, there is a very intense competition, as well as the unpredictability of customer desires and market trends that change at a rapid speed, resulting in a shorter product life cycle. The purpose of this article is to examine the industry of commercial kitchens and the main aspects could be the key of successfully launching shelf for serving lines to the market. The empirical research background for this study is defined by the performed survey-questionnaire. The results of the survey of enterprises that specialize in manufacturing professional kitchen equipment, as well as the results of the survey of customers who are interested in such products, are presented in this article. The aim of both surveys was to determine which success aspects the company should rely on, and which are the most important for successful product development and market launch. Based on the result of the research and the information which was gathered, a model for the successful development and launch of a shelf for serving lines was developed and proposed. It is a hybrid type model which is based on the principles of Stage-Gate model, Decision process model which was suggested by Kotler and Keller and Agile set of values and principles. It has 7 stages and, stages have 6 gates where the project is assessed every time. This model is a recombinational tool of launching the product to the market which could help to identify the problematic issues within the ongoing process in the company.

Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023).

In Europe, the combination of cabotegravir (CAB) with rilpivirine (RPV) has been approved as a dual injection long-acting (LA) therapy for the treatment of human immunodeficiency virus type 1 (HIV-1) infections in adults since December 2020. Studies have shown that between 36 and 61% of people living with HIV (PLWHIV) prefer LA therapy. However, there are no real-world data on the number of people receiving LA therapy, in Germany or internationally. The aim of this study was to assess the current situation and trends in usage of LA therapy for the treatment of HIV-1 in Germany. Based on pharmacy prescription data derived from Insight Health, the monthly number of prescriptions for oral CAB, CAB-LA, and RPV-LA over the entire period of availability in Germany was analyzed and evaluated (May 2021 to December 2023). The number of 1st and 2nd initiation injections and subsequent maintenance injections was calculated on the basis of the prescriptions for oral CAB initiation. The bimonthly schedule resulted in two growing cohorts from September 2021 with an estimated 14,523 CAB-LA prescriptions over the entire period. Accordingly, in December 2023, there were approximately 1,364 PLWHIV receiving LA therapy, of whom 1,318 were receiving maintenance therapy. Only treatments with bimonthly regimens were carried out. Accounting for people not covered by statutory health insurance (~13%), a total of ~1,600 PLWHIV were receiving LA therapy in Germany in December 2023. The average rounded annual cost of therapy in 2023 was €11,940 (maintenance therapy with initiation) and €10,950 (maintenance therapy without initiation). To our knowledge, this is the first study of real-world use and number of people receiving LA therapy. A strength of our study is the nearly complete coverage of people with statutory health insurance in Germany. The predicted demand for LA therapy does not match the actual number of people receiving LA therapy. Although the number of PLWHIV receiving LA therapy increased steadily, they accounted for just under 2% of the estimated total number of people receiving HIV therapy in Germany in 2023, almost 2 years after the market launch. No significant increase in prescriptions is expected; on the contrary, the trend is leveling off and is unlikely to change drastically in the near future. Hence, the need for this mode of therapy in Germany appears to be limited. Follow-up studies at regular intervals on the further course would be useful and are recommended, as well as investigations into the possible reasons for the slow uptake to inform public health experts and possibly broaden treatment options.

Development of the TOD.id Mobile App

The rise of large cities worldwide has spurred the emergence of Transit Oriented Development (TOD) as an urban planning concept. Indonesia, including Jakarta, has begun implementing TOD strategies. To facilitate TOD in Indonesia, this study proposes a conceptual mobile app, TOD.id, informed by preliminary research. It introduces a novel tax approach, Land Value Capture (LVC) tax, to address funding challenges, which account for up to 53.8% of the problem. However, TOD.id remains in a developmental phase, with all features in the conceptual stage, making it unsuitable for immediate market launch. During this stage, this research aims to enhance the TOD.id mobile app by refining existing features and exploring potential new functionalities, which will be based by literature review and benchmarking against similar existing apps in Indonesia. The study employs a desk study method, a qualitative benchmark study method, and the collection of qualitative data. The outcomes of this research are expected to pave the way for the optimal realization of TOD.id in the Indonesian market, aligning with the projections from previous studies.

A Comparative Analysis of Generic Drug Assessment and Regulatory Approval in the USA, Europe and India.

The Abbreviated New Drug Application (ANDA) is used for the regulatory submission of generic drugs, which are pharmaceutical equivalents to brand-name drugs and distributed without patent protection. Different countries have their own regulatory requirements for the approval of generic drugs, enforced by authorities such as the CDSCO in India, EDQM in Europe, and USFDA in the United States. This review aims to compare the regulatory processes and requirements for generic drug approval in India, Europe, and the US, highlighting key differences and challenges. The involvement of regulatory authorities in the drug development process is crucial for expediting approval and addressing queries, helping to minimize delays. The Common Technical Document (CTD) format is employed across regions to harmonize submission requirements. This study underscores the differences in dossier submission for generics across the three regions, illustrating India's position in the global generic drug approval landscape. By comparing approval requirements, this work provides insight into the hurdles India must overcome to streamline its approval process. The ANDA allows generic manufacturers to submit bioequivalence studies, using the original innovator's safety and efficacy data. However, obtaining approval simultaneously from multiple regulatory authorities remains a challenging task. Careful review of regulatory documents by skilled personnel can reduce regulatory queries, ultimately accelerating the market launch of generic drugs. This review provides a comprehensive overview of the generic drug approval process, emphasizing the need for harmonization and improved efficiency in India's regulatory framework.

The Challenges of Testing Flexible Electronics

Innovations in product design have ushered in flexible electronic products, adapting to diverse user needs from foldable smartphones to smart wearables. Successful market launches depend on rigorous testing for quality and durability. This article advocates for comprehensive testing procedures as flexible electronics move towards standardization and illustrates the working method of the Nuremberg-based test centre of MSWtech and BayflexSolutions.

Deep convolutional autoencoders for the time–space reconstruction of liquid rocket engine flames

The integration of high-fidelity numerical simulations into the rocket engine design-cycle promises to cut costs in an ever more competitive launch market. Although still being intractable in the optimization of most of combustion devices, their potential can be harnessed via appropriate reduced order models (ROMs). In recent years, significant progress has been made in the ROM literature through the adoption of non-linear methods, coming from the realm of deep learning. These methods promise to deliver where conventional linear techniques, such as Proper Orthogonal Decomposition (POD), fall short due to their inherent qualities.In the current work, we carry out a first attempt to develop purely data-driven emulators for a shear-coaxial liquid rocket engine injector. In particular, a Convolutional Neural Network autoencoder (CNN-AE) with a Multi-Layer Perceptron (MLP) latent dynamics encoder architecture is considered. The main objective is to assess the capacity of autoencoders based models to reconstruct, in time and space, the instantaneous temperature field of a non-canonical, complex, reactive, flow configuration. The data used is made of Large Eddy Simulations (LES) of three distinct, real-life inspired, injector configurations.The autoencoder based models show superior reconstruction capabilities compared to POD with similar latent-space dimension. Moreover, the time–space reconstructed fields preserve the spectral content of the snapshots, with only a small loss in gain at high frequencies. These results serve as proof-of-concept for further developments on surrogate models of liquid rocket engine injectors.

Cost estimation for launch vehicle families considering uncertain market scenarios

When optimizing the staging of a launch vehicle, usually a reference mission with a fixed payload mass is used to determine the specific launch cost (or a surrogate thereof, e.g. total mass or dry mass). While this approach neglects suboptimal loading, it delivers sufficiently good results for the evaluation of an individual launcher if the design mission is well known. However, this approach does not capture the full range of payloads that a launch vehicle is expected to launch during its operational lifetime. In order to estimate the cost and subsequently optimize the staging of such launch vehicle families, a full launch scenario has to be considered. The cost of an individual launch vehicle loses importance and the deciding factor is the total cost associated with launching the specified scenario. However, estimates of the future market inevitably include large uncertainties. These uncertainties and their impact are ideally considered and quantified when assessing the specific recurring cost of a single launch vehicle. The consideration of a whole launch market scenario is especially relevant when evaluating a family of launch vehicles, an option currently being discussed for future European launchers. In this case, the distribution of the payloads onto the different members of the launch vehicle family has to be optimized in order to reach the lowest possible cost. Within this manuscript, a method that allows the determination of the recurring cost of such a launcher family based on a launch market scenario including uncertainties is proposed. Based on the launch numbers derived from the combinatorial optimization, parametric cost models for recurring and non-recurring cost are adapted and applied to three possible future launch vehicle families.